Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | DGAT1 | O75907 | 14/20 | 0.45 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14984446 | 1.00 | ALDH1A1 (0.48) | ALDH1A1LMNAMAPTCYP2C9DGAT1 | |
| SCHEMBL15043518 | 0.88 | ALDH1A1 (0.48) | ALDH1A1LMNAMAPTCYP2C9DGAT1 | |
| SCHEMBL14984444 | 0.88 | ALDH1A1 (0.48) | ALDH1A1LMNAMAPTCYP2C9DGAT1 | |
| SCHEMBL13008024 | 0.86 | IDO1 (0.55) | ALDH1A1LMNAMAPTDGAT1IDO1 | |
| SCHEMBL10197495 | 0.86 | IDO1 (0.55) | ALDH1A1LMNAMAPTDGAT1IDO1 | |
| SCHEMBL602376 | 0.86 | CYP2C9 (0.48) | ALDH1A1LMNAMAPTCYP2C9DGAT1 | |
| SCHEMBL14984455 | 0.86 | ALDH1A1 (0.52) | ALDH1A1LMNAMAPTCYP2C9DGAT1 | |
| SCHEMBL382897 | 0.85 | ESR2 (0.56) | ALDH1A1LMNAMAPTCYP2C9DGAT1 | |
| SCHEMBL382898 | 0.85 | ESR2 (0.56) | ALDH1A1LMNAMAPTCYP2C9DGAT1 | |
| SCHEMBL10197496 | 0.85 | DGAT1 (0.47) | ALDH1A1LMNAMAPTCYP2C9DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595970-B1 | DERIVATIVES OF OXADIAZOLE AND PYRIDAZINE, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | SANOFI SA (FR) | 2015-01-07 | — | — | EP | disclosed |
| US-8546391-B2 | Thiadiazole and oxadiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-10-01 | — | — | US | disclosed |
| CN-103201271-A | Derivatives of oxadiazole and pyridazine, their preparation and their application in therapeutics | SANOFI SA | 2013-07-10 | — | — | CN | disclosed |
| US-20130137691-A1 | DERIVATIVES OF OXADIAZOLE AND PYRIDAZINE, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | SANOFI (FR) | 2013-05-30 | — | — | US | disclosed |
| EP-2595970-A1 | DERIVATIVES OF OXADIAZOLE AND PYRIDAZINE, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | SANOFI (FR) | 2013-05-29 | — | — | EP | disclosed |
| US-20120040984-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-16 | — | — | US | disclosed |
| WO-2012011081-A1 | DERIVATIVES OF OXADIAZOLE AND PYRIDAZINE, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | SANOFI (FR) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040984-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | OXA1L, CYP11B2, CYP11B1 | ALDH1A1 126/4885LMNA 4261/4885MAPT 2666/4885 |
| US-20130137691-A1 | DERIVATIVES OF OXADIAZOLE AND PYRIDAZINE, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | XDH, NOX3, OXA1L | ALDH1A1 565/4885LMNA 1049/4885MAPT 4122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.